Clinical Trials
27 trialsTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
IMMUNORARE5
Hospices Civils de Lyon
KEYNOTE 158
Merck Sharp & Dohme LLC
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
P-PRRT
CHU de Quebec-Universite Laval
EVENET
AC Camargo Cancer Center
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
SCRI Development Innovations, LLC
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
RAMSETE/CDE16
Novartis
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
GI-NETorPNET
Mateon Therapeutics
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
EPO906 in Carcinoid and Other Neuroendocrine Tumors
Novartis
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
68Ga
Vanderbilt-Ingram Cancer Center
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Cylene Pharmaceuticals